Jemily Malvar
Overview
Explore the profile of Jemily Malvar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
1206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma J, Foster J, Rassekh S, Malvar J, Chi Y, Sauer H, et al.
Pediatr Blood Cancer
. 2025 Mar;
:e31631.
PMID: 40032793
Background: Cisplatin is used to treat solid tumors but causes irreversible hearing loss. Pedmark, a formulation of sodium thiosulfate (STS), is approved to prevent cisplatin-induced hearing loss (CIHL). Prior to...
2.
Shah N, Schafer E, Chi Y, Malvar J, Heym K, Place A, et al.
Pediatr Blood Cancer
. 2025 Feb;
:e31584.
PMID: 39937083
Introduction: Vincristine sulfate liposome injection (VSLI), a liposomal formulation of vincristine, may be better tolerated than standard aqueous vincristine and enable dose intensification. Procedures: Based on single-agent tolerability, activity, and...
3.
Mashiach D, Mead P, Carneiro K, Malvar J, Knight S, Young G
Pediatr Blood Cancer
. 2024 Oct;
71(12):e31351.
PMID: 39367598
Background: Hemophilia A (HA) is an X-linked bleeding disorder diagnosed by a deficiency in factor VIII (FVIII). For severe HA (SHA), prophylaxis clotting factor concentrates (CFC) has become the standard...
4.
Keller M, Hanley P, Chi Y, Aguayo-Hiraldo P, Dvorak C, Verneris M, et al.
Nat Commun
. 2024 Apr;
15(1):3258.
PMID: 38637498
Viral infections remain a major risk in immunocompromised pediatric patients, and virus-specific T cell (VST) therapy has been successful for treatment of refractory viral infections in prior studies. We performed...
5.
Verma A, Chi Y, Malvar J, Lamble A, Chaudhury S, Agarwal A, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339248
Improvements in survival have been made over the past two decades for childhood acute myeloid leukemia (AML), but the approximately 40% of patients who relapse continue to have poor outcomes....
6.
Kuo C, Malvar J, Chi Y, Kim E, Shah R, Navid F, et al.
Cancer Med
. 2023 Oct;
12(20):20231-20241.
PMID: 37800658
Background: Thoracotomy is considered the standard surgical approach for the management of pulmonary metastases in osteosarcoma (OST). Several studies have identified the advantages of a thoracoscopic approach, however, the clinical...
7.
Cohen-Cutler S, Kaplan C, Olch A, Wong K, Malvar J, Constine L, et al.
Oncologist
. 2023 Jun;
28(9):e784-e792.
PMID: 37284853
Background: Screening guidelines for childhood cancer survivors treated with radiation currently rely on broad anatomic irradiated regions (IR) to determine risk for late effects. However, contemporary radiotherapy techniques use volumetric...
8.
Orgel E, Knight K, Chi Y, Malvar J, Rushing T, Mena V, et al.
Clin Cancer Res
. 2023 May;
29(13):2410-2418.
PMID: 37134194
Purpose: Cisplatin-induced hearing loss (CIHL) is common and permanent. As compared with earlier otoprotectants, we hypothesized N-acetylcysteine (NAC) offers potential for stronger otoprotection through stimulation of glutathione (GSH) production. This...
9.
Doan A, Huang H, Hadar A, Malvar J, Rushing T, Raca G, et al.
Br J Haematol
. 2023 May;
202(1):e3-e6.
PMID: 37129267
No abstract available.
10.
Goldsmith K, Park J, Kayser K, Malvar J, Chi Y, Groshen S, et al.
Nat Med
. 2023 Apr;
29(5):1092-1102.
PMID: 37012551
Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study evaluating lorlatinib with and without chemotherapy in children...